Clinical trialNCT06001385Active, not recruitingPhase 2Interventional

HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis

SponsorCenter for International Blood and Marrow Transplant ResearchEnrollment313Acute LeukemiaAcute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Lymphocytic LeukemiaChronic Myeloid LeukemiaChronic Myelomonocytic Leukemia+5 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor (MMUD) . The main question\[s\] it aims to answer are: * Does a reduced dose of PTCy reduce the occurrence of infections in the first 100 days after transplant? * Does a reduced dose of PTCy maintain the same level of protection against Graft Versus Host Disease (GvHD) as the standard dose of PTCy?

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Ginna Laport, MD
NMDP
Study Chair
clinicaltrials.gov ↗
Steven Devine, MD
NMDP
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

32 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Mayo Clinic Arizona
Phoenix, Arizona, United States
Honor Health
Scottsdale, Arizona, United States
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
City of Hope
Duarte, California, United States
University of California San Francisco
San Francisco, California, United States
Stanford University
Stanford, California, United States
Colorado Blood Cancer Institute at Presbyterian St. Luke'S
Denver, Colorado, United States
Mayo Clinic Jacksonville
Jacksonville, Florida, United States
University of Miami Sylvester Cancer Center
Miami, Florida, United States
Moffitt Cancer Center
Tampa, Florida, United States
Emory University
Atlanta, Georgia, United States
Greenbaum Cancer Center University of Maryland
Baltimore, Maryland, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Tufts University
Boston, Massachusetts, United States
Karmanos Cancer Institute
Detroit, Michigan, United States
University of Minnesota
Minneapolis, Minnesota, United States
Mayo Clinic
Rochester, Minnesota, United States
Barnes Jewish Hospital / Washington University
St Louis, Missouri, United States
Memorial Sloan Kettering Cancer Center - Adults
New York, New York, United States
University of North Carolina
Chapel Hill, North Carolina, United States
Ohio State Medical Center
Columbus, Ohio, United States
Oregon Health & Science University
Portland, Oregon, United States
the Center for Bone Marrow Transplantation at Geisinger
Danville, Pennsylvania, United States
Abramson Cancer Center
Philadelphia, Pennsylvania, United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Tristar Centennial
Nashville, Tennessee, United States
St. David'S South Austin Medical Center
Austin, Texas, United States
Md Anderson Cancer Center
Houston, Texas, United States
Methodist Hospital San Antonio
San Antonio, Texas, United States
University of Virginia Health System
Charlottesville, Virginia, United States
Fred Hutchinson Cancer Center
Seattle, Washington, United States
Froedtert & the Medical College of Wisconsin
Milwaukee, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

BusulfanCyclophosphamideFludarabineMelphalanMesnaMycophenolate mofetilPost-Transplant CyclophosphamideTacrolimus

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 8 Dec 2023
Primary completion: 24 Dec 2026
Completion: 30 Dec 2026
Last update posted: 17 Aug 2026
Registered enrollment: 313
Registry id: NCT06001385

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.